SEC Form 4 · accession 0001209191-19-013584
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fred E Cohen
Director
Period of report
Feb 22, 2019
Accepted (ET)
Feb 26, 2019 · 4:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 22, 2019 | M | 10,000 | $26.01 | A | 77,619 | D | |
| Common StockF1,F2 | Feb 22, 2019 | S | 9,307 | $78.8027 | D | 68,312 | D | |
| Common StockF1,F3 | Feb 22, 2019 | S | 693 | $79.5698 | D | 67,619 | D | |
| Common Stock | holding | — | — | — | 6,068 | I | By the Jane K Cohen Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy) | $26.01 | Feb 22, 2019 | M | 10,000 | D | Jun 12, 2016 | Jun 12, 2026 | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F2Represents weighted average sale price. Actual sale prices ranged from $78.42 to $79.37.
- F3Represents weighted average sale price. Actual sale prices ranged from $79.50 to $80.02.